Oruka Therapeutics, Inc. (ORKA) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(31.8) million | $(21.0) million |
| Operating Expenses | $36.4 million | $25.1 million |
| Research & Development (R&D) | $29.1 million | $19.9 million |
| General & Administrative (G&A) | $7.3 million | $5.2 million |
| Interest Income | $4.6 million | $4.1 million |
| Cash, Cash Equivalents & Marketable Securities | $496.0 million | $477.4 million (Dec 31, 2025) |
| Accumulated Deficit | $(221.0) million | $(189.2) million (Dec 31, 2025) |
| Net Cash Used in Operating Activities | $(23.6) million | $(20.9) million |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by $10.8 million (52%) compared to Q1 2025, driven primarily by higher R&D and G&A expenses.
- R&D Expense Growth: R&D expenses rose by $9.2 million (46%). This increase was due to higher external costs for CROs/CMOs, increased personnel costs, and a $3.0 million milestone payment related to the dosing of the first patient in the Phase 2 trial for ORKA-002.
- G&A Expense Growth: G&A expenses increased by $2.1 million (41%), primarily due to increased personnel-related expenses and stock-based compensation.
- Capital Raises: During Q1 2026, the company raised $38.9 million net proceeds through its At-The-Market (ATM) offering program. Additionally, a subsequent event in April 2026 involved an underwritten public offering raising $700.4 million gross.
- Stock-Based Compensation: Total stock-based compensation expense was $7.0 million in Q1 2026, up from $4.9 million in Q1 2025.
Guidance, Outlook, and Risks
- Liquidity: Management expects existing cash, cash equivalents, and marketable securities (totaling $496.0 million as of March 31, 2026) to fund operations for at least twelve months. The April 2026 capital raise significantly extends this runway.
- Development Pipeline:
- ORKA-001 (IL-23p19): Phase 2a (EVERLAST-A) data announced in April 2026 showed 63.5% of participants achieved PASI 100 at Week 16. Phase 2b (EVERLAST-B) dosing commenced in December 2025.
- ORKA-002 (IL-17A/F): Phase 1 results announced in January 2026 showed a half-life of ~75-80 days. Phase 2 (ORCA-SURGE) dosing commenced in February 2026.
- Strategic Collaboration: On May 1, 2026, the company entered into a global exclusive collaboration with Halozyme Hypercon, Inc., licensing Hypercon technology for IL-23p19. This agreement includes potential milestone payments up to $176.5 million.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for substantial additional capital to fund future operations, reliance on third-party manufacturers (including potential impacts from the BIOSECURE Act on foreign suppliers), and the competitive landscape in the I&I market.
Investor Verification Checklist
- Verify the impact of the $3.0 million milestone payment on the Q1 2026 R&D expense and confirm the specific clinical trigger (first patient dosing in ORKA-002 Phase 2).
- Review the details of the April 2026 underwritten offering ($700.4 million gross) and the May 2026 Halozyme collaboration to assess future cash runway and potential milestone obligations.
- Monitor the Phase 2a (EVERLAST-A) data for ORKA-001, specifically the 63.5% PASI 100 rate, and the upcoming Phase 2b data timeline.
- Assess the company's reliance on foreign CMOs (e.g., WuXi Biologics) and the potential operational impact of the BIOSECURE Act enacted in December 2025.
- Confirm the status of the ATM offering program and remaining capacity under the $200 million Sales Agreement.